September 12, 2019

Research conducted since 2015 shows that more companies are tracking aggregate spend on individual HCPs than in 2015. However, most teams still do not enforce an annual cap on compensation amounts. Among those that do, the majority have separate caps by activity. In particular, specific caps for speaking engagements, which have been closely scrutinized by regulators in the past, are very common.

Increasingly, regulators appear to be placing scrutiny on aggregate spend by companies as a potential anti-kickback violation. This is being fueled by reporting requirements that effectively place a lot of data in the public domain and allow regulators to quickly identify anomalous compensation amounts.

Questions about this post or our services? Contact us directly.

ABOUT THE AUTHOR

Jacob Presson is the manager of FMV Services at Cutting Edge Information. In this role, he delivers premier FMV data to life sciences companies to ensure compliant HCP engagements. As an experienced analyst, Mr. Presson believes that robust data is the best tool for informed decision making. He is a graduate of N.C. State University.

Contact Us
REQUEST A DEMO